Close Menu

NEW YORK (GenomeWeb News) – Genomas has won a $1.4 million grant from the National Institutes of Health to develop pharmacogenomic technology that will help doctors predict drug efficacy and side-effect risk for neuropsychiatric disease patients.

The company plans to use the Small Business Innovation Research grant to continue developing its PhyzioType Systems, which use genetic polymorphisms found through array genotyping and an algorithm to help doctors develop personalized drug prescriptions for antidepressants and antipsychotics.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers trace DNA on a clay pipe found at a former slave site to a population that lives in what is now Sierra Leone, the Washington Post reports.

Two researchers report on their genetic analysis of samples from a shawl thought to belong to a victim of Jack the Ripper, ScienceInsider reports.

Japan is to release rules governing some gene-edited food, according to NHK World.

In PLOS this week: computational strategy for improving gene set analysis testing, miRNAs linked to sleep apnea, and more.

Mar
20
Sponsored by
Qiagen

This webinar will discuss how a new multiplexed testing system can help physicians rapidly diagnose acute respiratory infections in the near-patient setting.

Mar
21
Sponsored by
Loop Genomics

This webinar provides a comparison of next-generation sequencing (NGS) approaches for human transcriptome sequencing, including short-read Illumina sequencing and synthetic long-read sequencing technology.

Mar
28
Sponsored by
Qiagen

The Human Gene Mutation Database (HGMD) is a manually curated, comprehensive collection of disease-causing, germline mutations. Since 1996, a team of experts has manually catalogued over a quarter of a million mutations for the database.  

Apr
11
Sponsored by
Bionano Genomics

This webinar will review a recent study that applied whole-genome sequencing and optical genome mapping to identify a large number of previously undetected somatic structural variants in leukemia samples.